Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy

Background: In the U.S., more than 50% of ovarian cancer patients die within 5 years of diagnosis, highlighting the need for innovations such as engineered T cell therapies. Mesothelin (Msln) is an attractive immunotherapy target for this cancer, as it is overexpressed by the tumor and contributes t...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	bioRxiv
Hlavní autori:	Anderson, Kristin G, Oda, Shannon K, Bates, Breanna M, Burnett, Madison G, Magdalia Rodgers Suarez, Ruskin, Susan L, Greenberg, Philip D
Médium:	Paper
Jazyk:	English
Vydavateľské údaje:	Cold Spring Harbor Cold Spring Harbor Laboratory Press 31.07.2021 Cold Spring Harbor Laboratory
Vydanie:	1.1
Predmet:	Adoptive immunotherapy Antitumor agents Apoptosis Cell activation Cell death Cell proliferation Cell survival Cell therapy Cytokines FasL protein Fusion protein Immunology Immunomodulation Immunotherapy Invasiveness Lymphocytes Lymphocytes T Ovarian cancer Phenotypes Solid tumors T cell receptors Tumor cells Tumor microenvironment Tumor-infiltrating lymphocytes Tumors Adoptive T cell Immunotherapy Immuno-modulatory Fusion Protein High Grade Serous Ovarian Cancer Immunocompetent Mouse Model
ISSN:	2692-8205, 2692-8205
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!